Regado Biosciences Receives Consensus Rating of “Hold” from Analysts (NASDAQ:RGDO)
Regado Biosciences (NASDAQ:RGDO) has received a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, AnalystRatingsNetwork reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $4.96.
A number of research firms have recently commented on RGDO. Analysts at Zacks upgraded shares of Regado Biosciences from a “neutral” rating to an “outperform” rating in a research note on Thursday. They now have a $1.20 price target on the stock. Separately, analysts at Jefferies Group downgraded shares of Regado Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $1.50 price target on the stock, down previously from $7.50. Finally, analysts at Deutsche Bank downgraded shares of Regado Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $2.00 price target on the stock, down previously from $14.00.
Shares of Regado Biosciences (NASDAQ:RGDO) traded up 1.79% on Friday, hitting $1.1299. The stock had a trading volume of 120,472 shares. Regado Biosciences has a 52 week low of $1.09 and a 52 week high of $14.10. The stock has a 50-day moving average of $2.55 and a 200-day moving average of $6.18. The company’s market cap is $38.0 million.
Regado Biosciences (NASDAQ:RGDO) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.51) by $0.12. Analysts expect that Regado Biosciences will post $-2.38 EPS for the current fiscal year.
Regado Biosciences, Inc is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.